MiNK Therapeutics, Inc. (INKT) Misses Q4 EPS by 54c

MiNK Therapeutics, Inc. (NASDAQ: INKT) reported Q4 EPS of ($0.62), $0.54 worse than the analyst estimate of ($0.08).

For earnings history and earnings-related data on MiNK Therapeutics, Inc. (INKT) click here.

You May Also Be Interested In

• Ciena beats estimates on strong AI-driven demand, shares rise
• Victoria's Secret & Co. (VSXY) Tops Q2 EPS by 20c ; Offers Guidance
• DA Davidson Reiterates Buy Rating on Barrick Gold Corp. (GOLD)